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forms of technology to ensure the safest delivery 
of the intervention.
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Targeted Temperature Management after Cardiac Arrest
To the Editor: Nielsen and coauthors (Dec. 5 is-
sue)1 show the importance of avoiding hyperther-
mia in patients who have had a cardiac arrest. 
However, if the clinical objective is to improve 
the neurologic outcome, it is important to define 
the expected neurologic outcome in individual 
patients. Studies have shown that the severity of 
neuronal lesions is dependent on the delay in ini-
tiation of cooling after reperfusion.2
In the article by Nielsen et al., the studied 
patients had a median return of spontaneous 
circulation of 25 minutes, with a wide interquar-
tile range of 18 to 40 in the hypothermic group 
and 16 to 40 in the normothermic group. In pro-
longed cardiac arrest, we do not expect that a 
reduction of neurologic metabolism by hypother-
mia will have a real effect on already damaged 
structures.
We should not conclude, on the basis of this 
trial, that hypothermia is simply an antihyper-
thermic strategy. Not all cardiac arrests are 
equal in terms of the time to return of sponta-
neous circulation. We should identify the sub-
groups of patients who can benefit from this 
form of therapy.
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To the Editor: Nielsen et al. confirm that fever 
should be avoided in resuscitated patients. How-
ever, several unanswered questions remain be-
fore abandoning therapeutic hypothermia in pa-
tients after cardiac arrest. One key issue is the 
potential benefit of early cooling initiated during 
cardiopulmonary resuscitation (CPR).
Pathophysiological mechanisms1 as well as 
experimental data suggest a benefit of early 
cooling, with intra-arrest cooling clearly superior 
to postresuscitation cooling.2 Thus, when moving 
from very early cooling in the experimental set-
ting to several hours of delay in clinical practice, 
we might miss the time window for the greatest 
effectiveness of hypothermia.3
Transnasal evaporative cooling can be induced 
in field conditions during CPR.4 The method 
induces continuous cooling, primarily to the 
brain, without the hemodynamic side effects 
recently seen with cold saline. Ongoing and fu-
ture studies may add important knowledge to 
this field of research.5
Nielsen et al. permitted a time to initiate 
cooling of 4 hours. We suggest that this time 
window may be crucial to influence outcome.
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To the Editor: The study by Nielsen et al. re-
vealed no significant difference between hypo-
thermic and near-normothermic treatment groups 
in patients after cardiac arrest and CPR in terms 
of their survival and neurologic outcome. This 
striking finding contradicts the previous under-
standing of the benefits of this form of therapy, 
and the next question seems to be whether there 
is any need to induce hypothermia in these pa-
tients.
However, the neurologic evaluation in Nielsen 
et al. was based on the Cerebral Performance 
Category (CPC) scale and a modified Rankin 
scale. These are simple tests devised for assess-
ing patients’ independent daily living and are in-
adequate for assessing cognitive prognosis, when 
mild cognitive impairment is a real concern in 
survivors of cardiac arrest.1-3 Thus, the findings 
of Nielsen et al. should not lead to changes in 
practice before the long-term prognosis of hypo-
thermic versus near-normothermic treatments 
and the patients’ recovery of cognitive function 
are investigated by means of recent advance-
ments in neurologic assessment.4 We ask for 
more clarification on this topic, which has to 
precede the decision to “drop the old habit” that 
may have brought a great deal of benefits to 
numerous patients during the past decade.
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To the Editor: Data from the study by Nielsen 
et al. showing that maintaining temperature at 
33°C and at 36°C have similar benefits in coma-
tose survivors of cardiac arrest originate from 
patients with an impressively short time to CPR 
and a higher percentage of bystander-initiated 
CPR (73%) than in previous clinical trials (49 to 
58%).1,2 Thus, whether such results could be 
widely applied to communities with a longer 
time to resuscitation remains to be clarified. 
Moreover, both midazolam and propofol provide 
additional neuroprotective effects3; however, doses 
of agents used were not specifically recorded. Fi-
nally, no specific guidelines for management of 
the postresuscitation syndrome were provided, 
yet it is known that early hemodynamic optimi-
zation may improve neurologic outcome after 
cardiac arrest.4 Because patients in the 33°C group 
more frequently had severe cardiovascular im-
pairment than those in the 36°C group (76% vs. 
70% on day 2 and 67% vs. 54% on day 3), inade-
quate organ perfusion may account for poten-
tially harmful effects of a lower target tempera-
ture; this was suggested by the higher proportion 
of deaths before prognostication from cardiac 
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causes or multiple organ failure observed in the 
33°C group.
Fabio Silvio Taccone, M.D. 
Antonio Dell’Anna, M.D.
Erasme Hospital 
Brussels, Belgium 
ftaccone@ulb.ac.be
No potential conflict of interest relevant to this letter was re-
ported.
1. Bernard SA, Gray TW, Buist MD, et al. Treatment of coma-
tose survivors of out-of-hospital cardiac arrest with induced hypo-
thermia. N Engl J Med 2002;346:557-63.
2. The Hypothermia after Cardiac Arrest Study Group. Mild 
therapeutic hypothermia to improve the neurologic outcome after 
cardiac arrest. N Engl J Med 2002;346:549-56. [Erratum, N Engl J 
Med 2002;346:1756.]
3. Harman F, Hasturk AE, Yaman M, et al. Neuroprotective 
effects of propofol, thiopental, etomidate, and midazolam in 
fetal rat brain in ischemia-reperfusion model. Childs Nerv Syst 
2012;28:1055-62.
4. Tagami T, Hirata K, Takeshige T, et al. Implementation of 
the fifth link of the chain of survival concept for out-of-hospital 
cardiac arrest. Circulation 2012;126:589-97.
DOI: 10.1056/NEJMc1401250
To the Editor: The large, randomized trial by 
Nielsen et al. showed no significant difference in 
survival between two strategies of targeted tem-
perature management (33°C vs. 36°C) in coma-
tose survivors of out-of-hospital cardiac arrest 
and therefore cast doubt on the results of earlier 
trials that evaluated induced hypothermia in this 
population. The investigators are to be commend-
ed for their rigorous trial with concurrent high 
rates of coronary angiography and structured, 
deferred approaches to prognostication and with-
drawal of care. Before abandoning 33°C as a 
treatment target, we should consider whether the 
benefit of this strategy may have been attenuated 
in this trial.
First, patients in the current study underwent 
randomization up to 4 hours after cardiac arrest 
and had a further 4 hours to achieve mean tem-
peratures below 34°C.1 A briefer time to the target 
temperature after cardiac arrest2 or in patients 
with ST-segment elevation myocardial infarction3 
may be required to modify reperfusion injury. 
Second, patients were sedated for 36 hours. Al-
though details were not provided, it is plausible 
that sedation with propofol may have attenuated 
the effect of temperature management on the 
reduction of reperfusion injury.4,5
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To the Editor: Nielsen and collaborators report 
that therapeutic hypothermia (33°C) conferred 
no outcome benefits after cardiac arrest, as com-
pared with strict fever control. This directly con-
tradicts the findings of two randomized, con-
trolled trials previously published in the Journal 
and other data supporting the use of therapeutic 
hypothermia after hypoxemic injury.1-3 How do 
we explain this? Should current guidelines be 
changed? The current study is large and well con-
ducted but has potential limitations. One is a rapid 
rate of rewarming, from 33°C to 36°C in 6 hours 
— a much faster rate than in previous trials. 
Rapid warming is harmful and can negate the 
benefits of therapeutic hypothermia.4,5 In addi-
tion, were all consecutive patients with cardiac 
arrest and return of spontaneous circulation 
screened for this study, or did physicians pre-
assess potential eligibility? Participating centers 
routinely used therapeutic hypothermia before 
this study and continued to treat nonstudy pa-
tients with it. Physicians could have subcon-
sciously selected patients with potential benefit 
for “routine” therapeutic hypothermia rather than 
refer for screening. The study enrolled an average 
of only one patient per center per month, possi-
bly indicating preselection.
These results could be misconstrued to advo-
cate abandoning temperature management after 
cardiac arrest altogether. We agree with the au-
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thors that the question should be what tempera-
ture to maintain, not whether temperature con-
trol is needed.
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To the Editor: With regard to the editorial ac-
companying the article by Nielsen and col-
leagues: we reflect on a key assertion that, “In 
contrast to a decade ago, one half instead of one 
third of patients with return of spontaneous cir-
culation after CPR can expect to survive hospital-
ization.”1 In fact, in 2002, the Hypothermia after 
Cardiac Arrest Study Group2 reported a hospital 
mortality of 43% (119 of 275 participants). The 
investigators participating in the Target Temper-
ature Management 33°C versus 36°C after Out-of-
Hospital Cardiac Arrest (TTM) trial now report a 
nearly identical hospital mortality of 44% (411 of 
939 participants).
Using the Australian and New Zealand In-
tensive Care Society Adult Patient Database 
(ANZICS APD), which includes data on more 
than 1.4 million intensive care unit (ICU) admis-
sions and more than 17,000 cardiac arrests, we 
determined the hospital mortality among pa-
tients with out-of-hospital cardiac arrest in Aus-
tralia and New Zealand from 2003 to 2012. We 
found a hospital mortality of 61% in 2003 and 
56% in 2012 and an ICU mortality of 46% in 
2003 and 48% in 2012 (Fig. 1). These findings 
and those mentioned above indicate that hospi-
tal mortality in Australia and New Zealand and 
in the European trial sites has not improved over 
time. Investigators must now seek new thera-
peutic interventions that protect the brain and 
improve mortality and neurologic outcomes af-
ter out-of-hospital cardiac arrest.3
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Figure 1. Hospital and ICU Mortality, 2003–2012.
Shown are hospital and ICU mortality among patients with cardiac arrest 
who were admitted to ICUs in Australia and New Zealand between 2003 
and 2012. I bars indicate 95% confidence intervals. Data are from the Aus-
tralian and New Zealand Intensive Care Society Adult Patient Database.
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Dr. Nielsen and colleagues reply: Perchiazzi 
et al., Nordberg et al., and Stub suggest that a 
delay in the initiation of temperature manage-
ment might influence outcome. The window of 
240 minutes from return of spontaneous circula-
tion to randomization was based on a study of 
data from the Hypothermia Network Registry, in 
which there was no association between time to 
the initiation of temperature management and 
6-month neurologic outcome.1 Other large ob-
servational studies have given similar signals.2 
Data from a recent randomized trial showed that 
early initiation of temperature management does 
not improve outcome.3 Intra-arrest cooling is, 
however, compelling, and we look forward to re-
sults from ongoing trials.
Perchiazzi et al. call for subgroup analyses to 
elucidate which patients might benefit from one 
of the interventions. The forest plot in Figure S2 
in the Supplementary Appendix (available with 
the full text of our article at NEJM.org) indicates 
a homogeneous intervention effect in five pre-
defined subgroups. Further multivariate analysis 
may give signals in any direction, but we would 
not recommend basing practice on inferences 
that at best could be hypothesis-generating.
Oh and colleagues ask for more detailed neu-
rologic assessment at follow-up, and we agree 
that the CPC scale and the modified Rankin 
scale represent crude measures. However, the 
CPC scale was used in trials introducing tem-
perature management in clinical practice. Data 
from more detailed assessment were collected but 
have not yet been published.4 Survival being the 
primary outcome, it is important to acknowl-
edge that the TTM trial was not powered to 
conclusively assess these measures.
Taccone and Dell’Anna comment on the high 
rate of bystander-initiated CPR in the TTM trial. 
During the past decade, there has been a con-
tinuous rise in bystander-initiated CPR, with 
positive consequences on overall outcome.5 The 
time to bystander-initiated CPR is naturally rele-
vant only for patients receiving such help and 
should be short. The time to bystander-initiated 
CPR was, to our knowledge, not reported in 
earlier trials on temperature management.
In response to Varon and Polderman: we con-
firm that sites consecutively screened all patients 
meeting inclusion criteria and randomly assigned 
every patient not meeting exclusion criteria. The 
baseline characteristics, active care (60% early 
angiography and 40% coronary intervention), 
and survival rates strongly contradict a selection 
of patients with a presumed poor outcome.
Whether goal-directed changes in post–car-
diac arrest care, sedatives, or the rewarming rate 
influence outcome is to our knowledge unknown 
and remains to be investigated in future ran-
domized clinical trials.
We disagree that our trial showed a benefit of 
avoiding fever; to do so, a no-intervention group 
would have been necessary. That said, we defi-
nitely would not advocate abandoning any tem-
perature management on the basis of the results 
of the TTM trial.
Niklas Nielsen, M.D., Ph.D.
Helsingborg Hospital 
Helsingborg, Sweden 
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Jørn Wetterslev, M.D., Ph.D.
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The editorialists reply: The data from ANZICS 
APD are a welcome addition to the longitudinal 
data on survival after cardiac arrest. We urge 
three points of caution regarding interpretation 
of these data. First, we wonder whether partici-
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on April 28, 2016. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
correspondence
n engl j med 370;14 nejm.org april 3, 2014 1361
pating ICUs adopted the use of a standard care 
plan including temperature management soon 
after the seminal articles,1,2 making the excellent 
survival rates depicted in this graph representa-
tive of the “temperature-management era.” Sec-
ond, the relevant comparison group for baseline 
survival from the Hypothermia after Cardiac Ar-
rest Study Group trial1 is the control group, which 
received no regimented care with respect to tem-
perature management. Although control patients 
were highly selected from a group with a high 
likelihood of survival, hospital mortality was 50% 
(69 of 138 patients), substantially higher than the 
hospital mortality of 44% (411 of 939 patients) in 
the TTM trial involving less selected patients. 
Third, if the ANZICS APD includes patients ad-
mitted to the ICU, it may not capture deaths that 
occur in the emergency department or during 
pre-ICU procedures. Despite this limitation, we 
do appreciate a modest decline in hospital deaths 
over the decade from more than 60% to its cur-
rent level.
Jon C. Rittenberger, M.D. 
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BMI and Mortality among Adults with Incident Type 2 Diabetes
To the Editor: Tobias et al. (Jan. 16 issue)1 
found no evidence of lower mortality among 
obese patients with incident type 2 diabetes, as 
compared with their normal-weight counterparts. 
An “obesity paradox” (i.e., an association between 
obesity and reduced mortality) had been reported, 
in particular in patient populations with a short 
survival time, whereas obesity by its nature is a 
risk factor for increased long-term mortality. Our 
earlier results show that short follow-up and the 
advanced age of populations with chronic dis-
eases are major limitations of such studies: over 
short periods, a high body-mass index (BMI) was 
not associated with increased mortality among 
patients with end-stage renal disease, but it was 
also not associated with increased mortality in 
the general population of equal age.2 Moreover, 
different underlying causes of the disease and 
coexisting illnesses impede a valid comparison 
between patients with a high BMI and those with 
a low BMI. Because of these limitations, it is not 
possible to translate such observations into causal 
interpretations — for example, to advise a high 
body weight in these patients. The findings by 
Tobias et al. are a timely reminder of the many 
biases that need to be taken into account before 
a causal interpretation of population data is pos-
sible.
Renée de Mutsert, Ph.D. 
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To the Editor: Although Carnethon et al.1 found 
a better prognosis in obese patients with type 2 
diabetes as compared with patients of “normal” 
weight, Tobias and colleagues did not find an 
obesity paradox. They explained that prior analy-
ses were limited by short follow-up, a small num-
ber of deaths, and a lack of data on smoking or 
undiagnosed diseases.
We are concerned, however, that neither study 
mentioned above accounted for fitness, espe-
cially because obese but fit persons with type 2 
diabetes have a considerably better prognosis 
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